Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 19, 2022

Ribociclib Plus Endocrine Therapy After Progression on Anti-Estrogen Therapy Plus CDK 4/6 Inhibition in Patients With Unresectable HR+/HER2− MBC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
J. Clin. Oncol 2022 Jun 08;40(17_suppl)LBA1004, K Kalinsky, MK Accordino, C Chiuzan, et al

Further Reading